Liver Toxicity Guidance Urges Sponsors To Include Risky Patients In Trials

FDA's recent draft guidance on drug-induced liver injury recommends drug developers enroll patients with preexisting liver disease in at least Phase III clinical trials, especially if the drug might eventually be used in such patients.